NCT05249777View on ClinicalTrials.gov

A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

573

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

August 5, 2022

Study Completion Date

September 10, 2022

Conditions
COVID-19
Interventions
DRUG

TD0069 hard capsule

TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.

DRUG

TD0069 Placebo

TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients

Trial Locations (2)

Unknown

Traditional Medicine Institute in Ho Chi Minh City, Ho Chi Minh City

Hanoi Hospital of Traditional Medicine, Hà Nội

All Listed Sponsors
collaborator

CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED

UNKNOWN

lead

Sao Thai Duong Joint Stock Company

INDUSTRY

NCT05249777 - A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter